Sanofi, Insmed among winners of CHMP recommendations (SNY)

The European Medicines Agency's expert panel has issued positive opinions for Sanofi's rilzabrutinib and Insmed's Brinsupri, with the latter potentially becoming the first EU-approved therapy for non-cystic fibrosis bronchiectasis, signaling significant new market opportunities for both companies. Conversely, Sanofi's Rezurock was rejected for chronic graft-versus-host disease, delaying its EU market entry, while several other major pharmaceutical firms, including Roche and Regeneron, received endorsements for new indications, expanding their European market reach.

Analysis

The European Medicines Agency's (EMA) expert panel has issued positive opinions for two new drug authorizations, signaling significant market opportunities. Insmed's Brinsupri (for non-cystic fibrosis bronchiectasis) received a strong endorsement and could become the first approved therapy for this indication in the EU, pending European Commission agreement. Sanofi's rilzabrutinib also received a positive opinion for immune thrombocytopenia, expanding its potential market reach.

Despite the positive opinion for rilzabrutinib, Sanofi (SNY) faces a setback with the rejection of Rezurock for chronic graft-versus-host disease. This rejection, despite the drug's availability in other regions, will delay its EU market access and temporarily limit growth from this specific indication. Sanofi's intent to seek reexamination suggests a prolonged regulatory pathway for Rezurock in the EU.

Beyond these primary developments, several other major pharmaceutical companies, including Roche, Regeneron, and Pfizer, received endorsements for new indications for existing drugs. This broad regulatory activity suggests a generally favorable environment for pharmaceutical innovation and market expansion within the EU. The overall sentiment for the news is strongly positive (0.7), reflecting optimism across the sector, though individual company impacts vary.

Key Decisions for Investors

• Investors should evaluate the market size and revenue potential for Insmed's Brinsupri, given its potential first-in-class status and strong positive sentiment (0.8) following EMA endorsement.